ArQule, Inc., a biotechnology company, engages in the research and development of cancer therapeutics in the United States. The company’s clinical-stage development programs include ARQ 197, a selective inhibitor of the c-Met receptor, which is in phase I clinical trial to treat patients with metastatic solid tumors; ARQ 501, which is in phase II clinical trials designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways; and ARQ 171, a second-generation E2F-1 compound that is in phase I clinical trial. It also has a preclinical and research pipeline, which includes B-RAF Kinase, HSP90, HDAC, and Eg5 programs. ArQule has an alliance with Hoffmann-La Roche to discover and develop drug candidates targeting the E2F biological pathway; and a research agreement with Boston Biomedical, Inc. the company was founded in 1993 and is headquartered in Woburn, Massachusetts.